1. Home
  2. TWST vs CPRX Comparison

TWST vs CPRX Comparison

Compare TWST & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$57.67

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$26.16

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWST
CPRX
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.9B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
TWST
CPRX
Price
$57.67
$26.16
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$46.25
$35.00
AVG Volume (30 Days)
1.0M
911.7K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
28.24
EPS
N/A
1.68
Revenue
$376,572,000.00
$119,072,803.00
Revenue This Year
$18.91
$9.20
Revenue Next Year
$15.07
$10.51
P/E Ratio
N/A
$15.08
Revenue Growth
20.32
16.39
52 Week Low
$23.30
$19.05
52 Week High
$57.88
$26.56

Technical Indicators

Market Signals
Indicator
TWST
CPRX
Relative Strength Index (RSI) 67.03 64.83
Support Level $41.85 $22.24
Resistance Level N/A N/A
Average True Range (ATR) 3.15 0.69
MACD 0.76 0.20
Stochastic Oscillator 93.81 91.29

Price Performance

Historical Comparison
TWST
CPRX

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: